Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

26.38 +0.70 (+2.73%)
Streaming Delayed Price Updated: 9:47 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Recap: Genmab Q1 Earnings ↗
 
Via Benzinga
News headline image
How To Attend Genmab Q1 2023 Earnings Conference Call ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Genmab ↗
 
Via Benzinga
News headline image
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst ↗
 
Via Benzinga
News headline image
Analyst Ratings for Genmab ↗
 
Via Benzinga
News headline image
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before. 
Via Investor's Business Daily
News headline image
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From Genmab
Via Business Wire
News headline image
P/E Ratio Insights for Genmab ↗
 
Via Benzinga
News headline image
This Foreboding Sign Looms Over Genmab's Chart ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Genmab ↗
 
Via Benzinga
News headline image
Earnings Outlook For Genmab ↗
 
Via Benzinga
News headline image
Alkermes Stock Sees Rising Relative Price Strength ↗
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
News headline image
Moderna Stock Getting Closer To Key Technical Benchmark ↗
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier. 
Via Investor's Business Daily
News headline image
Anavex Life Sciences Stock Shows Improved Price Strength Rating ↗
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
News headline image
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
3 Biotech Companies to Watch in 2023 ↗
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
News headline image
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
News headline image
Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
News headline image
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
From Genmab A/S
Via Business Wire
News headline image
Our 7 Top Biotech Stock Picks for 2023 ↗
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
News headline image
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating ↗
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
News headline image
3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗
These companies have long runways of growth ahead 
Via The Motley Fool
News headline image
Is AbbVie Stock a Buy Now? ↗
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
News headline image
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
News headline image
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.